WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Moderator

• 

• Clare Bailey, MD, FRCOphth

  Consultant Ophthalmologist
  Director of the Retinal Research and Treatment Unit
  Bristol Eye Hospital
  Bristol, United Kingdom

  Disclosures

  Clare Bailey, MD, FRCOphth, has the following relevant financial relationships:
  Consultant or advisor for: Alimera Sciences; Apellis Pharmaceuticals, Inc.; Bayer; Boehringer-Ingelheim; Janssen; Novartis; Roche
  Speaker or member of speakers bureau for: Bayer; Roche
  Research funding from: Bayer; Gyroscope; Roche

Faculty

• 

• David Brown, MD

  Professor of Ophthalmology
  Baylor College of Medicine
  Director of Research
  Retina Consultants of Houston
  Houston, Texas, United States

  Disclosures

  David Brown, MD, has the following relevant financial relationships:
  Consultant or advisor for : Adverum Biotechnologies Inc.; AGTC; Alexion Pharmaceuticals, Inc; Annexon, Inc.; Apellis Pharmaceuticals, Inc; Bayer UK; Biogen MA Inc.; Boehringer Ingelheim; Celltrion; Chengdu Kanghong Pharmaceutical; Clearside Biomedical Inc.; Coherus BioScience, Inc.; Gemini Therapeutics Inc.; Glaukos; Iveric Bio, Inc.; Kodiak Sciences Inc.; Lineage Cell Therapeutics; Medscape, LLC; Novartis Pharma AG; OPTOS PLC; Ray Therapeutics Inc.; Regeneron Pharmaceuticals, Inc; RetinAI Medical AG; Samsung Bioepis Co., Ltd.; Senju Pharmaceuticals Co., Ltd.; Smilebiotek Zhuhai Limited; Stealth BioTherapeutics Inc.; Verseon
  Research funding from : Adverum; Alderya; Alexion Pharmaceuticals, Inc; Alkahest; Alimera; Amgen; Annexon, Inc.; Apellis Pharmaceuticals, Inc.; Aura; Bayer UK; Boehringer Ingelheim; Boston Image Reading Center; Clearside Biomedical, Inc.; Eyepoint; Gemini Therapeutics Inc; Genentech/Roche; Graybug; Gyroscope; Johns Hopkins; Ionis; Irenix; Iveric; Kodiak Sciences Inc; Lowery Medical Research Group; Lumithera; Nanoscope; NEI/NH; Neurotech; NGM; Novartis Pharma AG; Ocular Therapeutix; Ocuphire Pharma, Inc; OIRRC; ONS; Opthea; Opthotech; OPTOS; Oxurion; Oysterpoint; Regeneron; REGENXBIO; Roche; SamChunDang; Samsung; Sandoz; Santen; Senju Pharmaceuticals Co., Ltd.; Stealth BioTherapeutics Inc; Unity; Xbrane; Zeiss
  Contracted researcher for : Adverum; Alderya; Alexion Pharmaceuticals; Alkahest; Alimera; Amgen; Annexon Inc.; Apellis Pharmaceuticals, Inc.; Aura; Bayer UK; Boston Image Reading Center; Boehringer Ingelheim; Clearside Biomedical, Inc.; Eyepoint; Gemini Therapeutics, Inc.; Genentech/Roche; Graybug; Gyroscope; Johns Hopkins; Ionis; Irenix; Iveric; Kodiak Sciences, Inc.; Lowery Medical Research Group; Lumithera; Nanoscope; NEI/NH; Neurotech; NGM; Novartis Pharma AG; Ocular Therapeutix; Ocuphire Pharma, Inc; OIRRC ONS; Opthea; Opthotech; OPTOS; Oxurion; Oysterpoint; Regeneron; REGENXBIO; Roche; SamChunDang; Samsung; Sandoz; Santen; Senju; Stealth BioTherapeutics, Inc.; Unity; Xbrane; Zeiss
  Stock options from: Adverum; Clearside

• 

• Roxane Hillier, MBChB, FRCOphth

  Consultant Ophthalmologist and Vitreoretinal Surgeon
  Research Lead for Ophthalmology
  Newcastle Eye Centre
  Honorary Senior Clinical Lecturer
  Newcastle University
  Newcastle-upon-Tyne, United Kingdom

  Disclosures

  Roxane Hillier, FRCOphth, has the following relevant financial relationships:
  Consultant or advisor for: Roche
  Speaker or member of speakers bureau for: Roche

• 

• Nancy Holekamp, MD

  Director of Retina Services
  Pepose Vision Institute
  St. Louis, Missouri, United States

  Disclosures

  Nancy Holekamp, MD, has the following relevant financial relationships:
  Consultant or advisor for: Adverum; Allergan; Annexon, Inc.; Apellis Pharmaceuticals, Inc.; Bayer; Cardinal; Clearside Biosciences; EyePoint Pharmaceuticals; Gemini Therapeutics, Inc.; Genentech; Gyroscope; Katalyst Surgical; Nacuity; NGM; Notal Vision; Novartis; Ocuphire; Outlook Therapeutics; Regeneron; Thea Laboratoires; Stealth BioTherapeutics, Inc.
  Speaker or member of speakers bureau for: Allergan; Genentech; Regeneron; Spark
  Research funding from: Gemini Therapeutics, Inc.; Genentech; Gyroscope; Notal Vision
  Patent beneficiary of: Katalyst Surgical (The Holekamp Drip Dropper)
  Stock options from: Gemini Therapeutics, Inc.; Nacuity
  Owns stock (publicly traded) in: Apellis; Gemini Therapeutics, Inc.

• 

• Laura Sararols Ramsay, MD

  Chief, Retina Unit
  Hospital General de Catalunya
  Barcelona, Spain
  Hospital General de Granollers
  Granollers, Spain

  Disclosures

  Laura Sararols Ramsay, MD, has the following relevant financial relationships:
  Consultant or advisor for: Bayer; Novartis; Roche
  Speaker or member of speakers bureau for: Bayer; Novartis; Roche
  Research funding from: Bayer; ISEE; Iveric; Kokidak; Novartis; Roche

Editor

• Katherine Carpenter, PhD

  Medical Education Director, WebMD Global, LLC

  Disclosures

  Katherine Carpenter, PhD, has the following relevant financial relationship
  Advisor or consultant for: Eisai (former), GW Pharmaceuticals (former)

Compliance Reviewer

• Lisa Simani, APRN, MS, ACNP

  Associate Director, Accreditation and Compliance

  Disclosures

  Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.